Dual Incretin Mimetic (GLP-1 & GIP) | Research Peptide for Weight Loss & Metabolic Optimization | For Research Use Only

Tirzepatide is a powerful dual receptor agonist targeting both GLP-1 and GIP pathways, developed for advanced research in obesity, insulin resistance, and type 2 diabetes. Its dual action enhances insulin secretion, reduces appetite, and improves energy balance, leading to superior outcomes compared to GLP-1-only agents such as Semaglutide.

The 30mg format is a balanced strength ideal for researchers seeking weekly dosing for sustained metabolic intervention studies.

🔍 Key Features

• GLP-1 + GIP Dual Receptor Activation

• Reduces Hunger, Slows Gastric Emptying

• Improves Blood Glucose Levels & Insulin Sensitivity

• Promotes Weight & Fat Mass Reduction

• Once-Weekly Research Dosing

• Well-Tolerated in Long-Term Trials

⚙️ Compound Details

• Peptide Name: Tirzepatide

• CAS Number: 2023788-19-2

• Molecular Formula: C₂₂₅H₃₄₀N₆₀O₆₅

• Molecular Weight: ~4813.45 g/mol

• Purity: ≥ 98% (HPLC Verified)

• Form: Lyophilised powder

• Unit Size: 30mg per vial

🧊 Storage & Handling

• Storage (Lyophilised): –20°C in dry, light-protected conditions

• Reconstitution: Use 1–2ml of sterile bacteriostatic water

• Post-Reconstitution: Store at 2–8°C and use within 10–14 days

• Avoid: Excess heat, light, or repeated freeze-thaw cycles

⚠️ For Research Use Only

Tirzepatide – 30mg is supplied exclusively for scientific research. It is not intended for human consumption, medical treatment, or diagnostic procedures.